Sanjiv Shah
Executive Director - Discovery Science Revolution Medicines
Dr. Sanjiv Shah is the Executive Director of Discovery Sciences at Revolution Medicines, where he leads efforts to refine and expand platform capabilities for discovering molecular glues and other novel small molecules targeting oncogenic proteins. His team is focused on building and deploying multi-modal assay platforms, spanning biochemical, biophysical, and cellular approaches, to address challenging targets in cancer, including those considered historically undruggable.
Prior to joining Revolution Medicines, Dr. Shah led large, multidisciplinary teams at Ginkgo Bioworks, Amgen, and Merck, with deep expertise in assay development, automation, and mechanism-driven drug discovery. Over the course of his career, he has contributed to advancing numerous clinical candidates and helped drive early-stage programs spanning immuno-oncology, neuroscience, and inflammation.
Seminars
- From concept to compound: How a mechanistically informed screen enabled the discovery of RAS(ON) stabilizing molecular glues
- Assay strategy: Building a platform of biochemical, biophysical, and cell-based assays to evaluate tri-complex formation and function
- Discovery at scale: Lessons learned from integrating covalent and non-covalent screening, and the importance of resolving kinetic and cooperative effects
